Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

Why Inovio Stock Sank Today

TheMotleyFool

0 0

Why Inovio Stock Sank TodayPhoto, wide shot, wide-angle lens, Clinical research organization, Blue hour, twilight, cool, ISO1200, slow shutter speed, photo by Michael Light: https://img.theapi.app/temp/c28f6640-54ba-4d2b-afbe-b5fd3b0ee19e.png

Shares of Inovio Pharmaceuticals (NASDAQ: INO) were sinking 6.6% as of 3:47 p.m. EST on Monday. The decline came after analysts gave mixed reviews to the biotech's phase 1 data from COVID-19 vaccine candidate INO-4800. These early-stage results were published in The Lancet's online clinical journal EClinicalMedicine on Dec. 24.

Piper Sandler analyst Christopher Raymond views INO-4800 as an "also-ran" compared to leaders in the coronavirus vaccine race. He remains highly skeptical of Inovio's prospects with its COVID-19 vaccine candidate.

Image source: Getty Images.

Source Fool.com

Like: 0

INO

Teilen